205 related articles for article (PubMed ID: 12504590)
1. Tsc2 null murine neuroepithelial cells are a model for human tuber giant cells, and show activation of an mTOR pathway.
Onda H; Crino PB; Zhang H; Murphey RD; Rastelli L; Gould Rothberg BE; Kwiatkowski DJ
Mol Cell Neurosci; 2002 Dec; 21(4):561-74. PubMed ID: 12504590
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
[TBL] [Abstract][Full Text] [Related]
3. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.
Tee AR; Fingar DC; Manning BD; Kwiatkowski DJ; Cantley LC; Blenis J
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13571-6. PubMed ID: 12271141
[TBL] [Abstract][Full Text] [Related]
4. mTOR cascade activation distinguishes tubers from focal cortical dysplasia.
Baybis M; Yu J; Lee A; Golden JA; Weiner H; McKhann G; Aronica E; Crino PB
Ann Neurol; 2004 Oct; 56(4):478-87. PubMed ID: 15455405
[TBL] [Abstract][Full Text] [Related]
5. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.
Inoki K; Li Y; Zhu T; Wu J; Guan KL
Nat Cell Biol; 2002 Sep; 4(9):648-57. PubMed ID: 12172553
[TBL] [Abstract][Full Text] [Related]
6. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
[TBL] [Abstract][Full Text] [Related]
7. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome.
Corradetti MN; Inoki K; Bardeesy N; DePinho RA; Guan KL
Genes Dev; 2004 Jul; 18(13):1533-8. PubMed ID: 15231735
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathogenesis of tuber formation in tuberous sclerosis complex.
Crino PB
J Child Neurol; 2004 Sep; 19(9):716-25. PubMed ID: 15563019
[TBL] [Abstract][Full Text] [Related]
9. Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse.
Way SW; McKenna J; Mietzsch U; Reith RM; Wu HC; Gambello MJ
Hum Mol Genet; 2009 Apr; 18(7):1252-65. PubMed ID: 19150975
[TBL] [Abstract][Full Text] [Related]
10. Cell-specific alterations of glutamate receptor expression in tuberous sclerosis complex cortical tubers.
Talos DM; Kwiatkowski DJ; Cordero K; Black PM; Jensen FE
Ann Neurol; 2008 Apr; 63(4):454-65. PubMed ID: 18350576
[TBL] [Abstract][Full Text] [Related]
11. Morphology of cerebral lesions in the Eker rat model of tuberous sclerosis.
Wenzel HJ; Patel LS; Robbins CA; Emmi A; Yeung RS; Schwartzkroin PA
Acta Neuropathol; 2004 Aug; 108(2):97-108. PubMed ID: 15185103
[TBL] [Abstract][Full Text] [Related]
12. Tuberous sclerosis as an underlying basis for infantile spasm.
Yeung RS
Int Rev Neurobiol; 2002; 49():315-32. PubMed ID: 12040899
[TBL] [Abstract][Full Text] [Related]
13. Single-cell Tsc1 knockout during corticogenesis generates tuber-like lesions and reduces seizure threshold in mice.
Feliciano DM; Su T; Lopez J; Platel JC; Bordey A
J Clin Invest; 2011 Apr; 121(4):1596-607. PubMed ID: 21403402
[TBL] [Abstract][Full Text] [Related]
14. [Expression of PI3K pathway proteins in refractory epilepsy associated with cortical malformation development].
Ni HC; Sun FH; Piao YS; Ma XL; Lu DH
Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):391-5. PubMed ID: 22932407
[TBL] [Abstract][Full Text] [Related]
15. Tuberous sclerosis: from tubers to mTOR.
Kwiatkowski DJ
Ann Hum Genet; 2003 Jan; 67(Pt 1):87-96. PubMed ID: 12556239
[TBL] [Abstract][Full Text] [Related]
16. c-myc Repression of TSC2 contributes to control of translation initiation and Myc-induced transformation.
Ravitz MJ; Chen L; Lynch M; Schmidt EV
Cancer Res; 2007 Dec; 67(23):11209-17. PubMed ID: 18056446
[TBL] [Abstract][Full Text] [Related]
17. Biallelic Mutations in
Winden KD; Sundberg M; Yang C; Wafa SMA; Dwyer S; Chen PF; Buttermore ED; Sahin M
J Neurosci; 2019 Nov; 39(47):9294-9305. PubMed ID: 31591157
[TBL] [Abstract][Full Text] [Related]
18. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2.
Garami A; Zwartkruis FJ; Nobukuni T; Joaquin M; Roccio M; Stocker H; Kozma SC; Hafen E; Bos JL; Thomas G
Mol Cell; 2003 Jun; 11(6):1457-66. PubMed ID: 12820960
[TBL] [Abstract][Full Text] [Related]
19. Prolonging the survival of Tsc2 conditional knockout mice by glutamine supplementation.
Rozas NS; Redell JB; McKenna J; Moore AN; Gambello MJ; Dash PK
Biochem Biophys Res Commun; 2015 Feb; 457(4):635-9. PubMed ID: 25613864
[TBL] [Abstract][Full Text] [Related]
20. Perturbed IFN-gamma-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-gamma treatment.
El-Hashemite N; Zhang H; Walker V; Hoffmeister KM; Kwiatkowski DJ
Cancer Res; 2004 May; 64(10):3436-43. PubMed ID: 15150095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
